ArticleInternational journal of obesity (2005)2021
Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity.
Article in International journal of obesity (2005), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 55 citations in OpenAlex.
- Metabolic Dysfunction-Associated Steatotic Liver Disease in the Aging Population: A Narrative Review of Pathophysiological Synergy, Diagnostic Challenges, and Tailored Management.Current gastroenterology reports · 2026Review
- Predictive modeling and clinical decision tools for risk stratification in steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Diagnostic Value of Serum Fibroblast Growth Factor 21 Combined with Fibrosis-4 Index for Hepatic Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways.JHEP reports : innovation in hepatology · 2026Article
- Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals.World journal of hepatology · 2026Article
- Noninvasive Markers of Hepatic Steatosis and Fibrosis Following Integrase Strand-Transfer Inhibitor Initiation in Women With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Article
- Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease.BMC gastroenterology · 2025Article
- Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE Thresholds and Diagnostic Accuracies for Detecting Hepatic Fibrosis in Patients with MASLD: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Sarcopenia, Muscle Mass and Protein Intake in Adults Older Than 65 Years After Earlier Bariatric Surgery.Journal of cachexia, sarcopenia and muscle · 2025Observational
- Perioperative Screening for Metabolic Dysfunction Associated Steatotic Liver Disease in People Undergoing Bariatric Surgery: A Pilot Study.Obesity surgery · 2025Article
- Non-Invasive Tests as a Replacement for Liver Biopsy in the Assessment of MASLD.Medicina (Kaunas, Lithuania) · 2025Review
- Validation of the BARD scoring system for fibrosis detection in nonalcoholic fatty liver disease.Bioinformation · 2025Article
- Prediction of hepatic fibrosis using the aspartate transaminase-to-platelet ratio index in children and adolescents with metabolic dysfunction-associated steatotic liver disease.BMC pediatrics · 2024Article
- Review
- Factors related to the presence of nonalcoholic fatty liver disease in patients with type 2 diabetes: a single center study.Clinical and experimental hepatology · 2023Article
- Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study.BMJ open · 2023Observational
- Significant fibrosis assessed by liver biopsy among Chinese bariatric surgery patients: A prospective cross-sectional study.Frontiers in endocrinology · 2023Article
- Article
- Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD].Metabolism open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-invasive scores, such as the non-alcoholic fatty liver disease (NAFLD) Fibrosis Score (NFS), are increasingly used for liver fibrosis assessment in patients with NAFLD. The aim of this study was to assess the applicability and reliability of non-invasive fibrosis scores in NAFLD patients with and without morbid obesity.
methodsThree hundred sixty-eight patients with biopsy-proven NAFLD identified between January 2012 and December 2015 were studied; 225 with morbid obesity (biopsy obtained during bariatric surgery) and 143 patients without (termed as "conventional").
resultsMedian age was 47 years, 57% were female. Median body mass index (BMI) was 42.9 kg/m
conclusionsOur data suggest that FIB-4 score is an accurate predictor of advanced fibrosis in NAFLD throughout all BMI stages. Without adjustment, NFS tends to overestimate fibrosis in morbidly obese NAFLD patients. This problem may be solved by implementation of an upper BMI limit (for NFS) or adjustment of diagnostic thresholds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.